top of page

July 28, 2025

Malone Wealth Advises Quantum BioPharma on Strategic Investment in Genius Group Ltd. (GNS)

​

BOISE, Idaho, July 28, 2025 (GLOBE NEWSWIRE) — Malone Wealth Ventures, LLC (“Malone Wealth” or the “Firm”), a fiduciary investment advisory firm committed to client protection and value-based investing, today announced that its client, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), has purchased 38,129 shares of Genius Group Ltd. (NYSE American: GNS) to hold on the Company’s balance sheet as a strategic investment.

​

This transaction follows extensive consultation and analysis conducted by Malone Wealth, which advised the Company to make this purchase based on three key pillars:

​

  1. The deep underlying value of Genius Group’s business model and assets
     

  2. The Company’s anticipated legal positioning in its upcoming RICO lawsuit against market manipulators
     

  3. A broader strategic alignment with Quantum’s commitment to fighting financial corruption and enhancing shareholder equity
     

Quantum BioPharma has been at the forefront of investor advocacy, including aggressive legal actions against naked short selling and market manipulation. The addition of Genius Group stock to its treasury reflects a targeted expansion into strategic equity holdings with strong upside potential and legal synergies.

​

“Malone Wealth continues to identify mispriced, high-conviction opportunities for our clients that align with their mission and shareholder mandate,” said Kevin Malone, CEO of Malone Wealth and Board Advisor to Quantum BioPharma. “We believe the Genius Group is not only fundamentally undervalued, but also uniquely positioned in the coming months as a central player in exposing systemic market abuses.”

This strategic stake in Genius Group complements Quantum BioPharma’s multi-pronged approach to shareholder value, including:

​

  • Advancing its Multiple Sclerosis drug candidate, Lucid-MS (see PR July 8, 2025)
     

  • Pending distribution of contingent value rights tied to ongoing litigation (see PR June 13, 2025)
     

  • Active lawsuits against major institutions for market manipulation totaling claims of over $700 million USD (see PR October 21, 2024)
     

The 38,129 GNS shares were purchased on the open market and are intended to be held long-term on the Company’s balance sheet.

Malone Wealth Ventures, LLC, which currently holds 829,730 Class B shares of Quantum BioPharma (representing ~21.8% of the outstanding Class B shares), continues to act as a key strategic advisor to the Company, having previously been compensated in the form of 30,000 shares and 60,000 RSUs for its consulting services.

​

As with previous equity acquisitions, all purchases are aligned with Quantum’s treasury strategy to accumulate undervalued, high-integrity assets that support both its core biopharma mission and broader mission of restoring transparency in capital markets.

 

About Quantum BioPharma Ltd.

​

Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.

​

Forward-Looking Information

This press release contains certain "forward-looking statements" within the meaning of applicable Canadian securities law. Forward-looking statements are frequently characterized by words such as "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements include the Company’s belief that its investment in GameStop represents a strategic opportunity and its expectation of a potential increase in GameStock’s stock price. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors, including the risk that the GameStock stock price may not increase as anticipated, that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects

 

Kevin Malone

CEO and President

Malone Wealth Ventures LLC

​

Malone Wealth Ventures LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Malone Wealth Ventures LLC and its representatives are properly licensed or exempt from licensure. This website is solely for informational purposes. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital. No advice may be rendered by Malone Wealth Ventures LLC unless a client service agreement is in place.

Malone Wealth Ventures LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Malone Wealth Ventures LLC and its representatives are properly licensed or exempt from licensure. This website is solely for informational purposes. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital. No advice may be rendered by Malone Wealth Ventures LLC unless a client service agreement is in place.

bottom of page